You are here
Pfizer reports its COVID-19 vaccine trial data shows long-term efficacy in adolescents
Primary tabs
Pfizer reports its COVID-19 vaccine trial data shows long-term efficacy in adolescents
Mon, 2021-11-22 15:13 — mike kraft Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years. Reuters
Nov 22 (Reuters) - Pfizer Inc (PFE.N) said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.
A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.
The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.
Pfizer and BioNTech (22UAy.DE) will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above ...
Country / Region Tags:
General Topic Tags:
Problem, Solution, SitRep, or ?:
Groups this Group Post belongs to:
- Private group -
Recent Comments